Cargo Therapeutics, Inc. (CRGO) is a clinical-stage biotechnology company focused on developing CAR T-cell therapies for cancer patients. The company demonstrates strong financial compliance with low debt levels, acceptable liquidity, and minimal non-permissible income. However, due to its small market capitalization and recent IPO status, it is not yet included in major Shariah-compliant indices. Business activities in oncology research are permissible under Shariah principles. Overall, while ratios support compliance, index exclusion leads to a non-compliant classification pending growth.